心脏移植受者合用伏立康唑时CYP2C19基因型对他克莫司剂量优化的影响
该回顾性研究纳入69例未用伏立康唑的对照和68例接受伏立康唑的心脏移植受者,评估他克莫司与伏立康唑相互作用及CYP2C19基因型对剂量调整的预测价值。结果显示相互作用个体差异大,他克莫司剂量变化倍数在CYP2C19快代谢者中显著低于中间或慢代谢者,且CYP2C19基因型和红细胞压积是剂量调整的独立预测因素。
要点
- 合用伏立康唑时他克莫司剂量变化个体差异超10倍,需个体化调整。
- CYP2C19快代谢者他克莫司剂量增加倍数低于中间或慢代谢者。
- CYP2C19基因型和红细胞压积是剂量调整的独立预测因素。
核心结论
- 心脏移植受者合用伏立康唑时,他克莫司剂量调整应考虑CYP2C19基因型和红细胞压积。
研究设计与样本
- 回顾性研究纳入69例未用伏立康唑的对照和68例接受伏立康唑的心脏移植受者,用Sanger测序检测CYP3A4*1G、CYP3A5*3和CYP2C19*2或*3。
主要发现
- 他克莫司与伏立康唑相互作用个体差异大,他克莫司剂量变化倍数范围1.28-13.00,C0/D变化倍数范围1.43-13.75。
- 他克莫司剂量变化倍数在CYP2C19快代谢者中显著低于中间或慢代谢者(4.06 ± 1.85 vs 5.49 ± 2.47,P = .0031)。
- CYP3A4和CYP3A5基因型间他克莫司剂量变化倍数无显著差异。
- CYP2C19基因型和红细胞压积是伏立康唑合用后他克莫司剂量调整的独立预测因素。
临床怎么用
- 心脏移植受者启动伏立康唑时,应依据CYP2C19基因型和红细胞压积个体化调整他克莫司剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Voriconazole remains the mainstay for the treatment of invasive fungal infections in heart transplant patients and can significantly increase tacrolimus exposure because of drug-drug interaction (DDI). However, the magnitude of this DDI is highly variable and difficult to predict. The purpose of this study was to present the characteristics of the DDI between tacrolimus and voriconazole, and further identify the various predictors of tacrolimus dose modification. METHODS: We retrospectively enrolled 69 heart transplant recipients who did not use voriconazole as the control and 68 patients received voriconazole treatment in voriconazole group. CYP3A4*1G, CYP3A5*3 and CYP2C19*2 or *3 were thereafter genotyped by Sanger sequencing. The dose of tacrolimus required to achieve the therapeutic concentrations and tacrolimus dose-corrected trough concentration (C0 /D) before and after VRC administration was evaluated. RESULTS: The DDI between tacrolimus and voriconazole displayed a large interindividual variability with more than 10-fold changes in tacrolimus dose (range 1.28-13.00) and C0 /D (range 1.43-13.75). In addition, the fold changes for the tacrolimus dose were associated with CYP2C19 genotype, which was found to be significantly lower in CYP2C19 extensive metabolizers than in CYP2C19 intermediate metabolizers or poor metabolizers (4.06 ± 1.85 vs 5.49 ± 2.47, P = .0031). However, no significant difference was found in both CYP3A4 and CYP3A5 genotypes. Moreover, CYP2C19 genotype and hematocrit acted as independent predicting factors for tacrolimus dose modification after voriconazole co-therapy. CONCLUSIONS: The findings of this study have identified the various important factors to adjust tacrolimus dosage when co-administrated with voriconazole in individual patients. CYP2C19 genotype and haematocrit should be considered when tailoring tacrolimus dose.
引用
- Huang X, Zhou Y, Zhang J, et al. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. Br J Clin Pharmacol. 2022. PMID: 35508605. doi:10.1111/bcp.15385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。